Pharmaceutical News

RSS

$Gabapentinoids may increase hip fracture risk in older adults$

Gabapentinoids may increase hip fracture risk in older adults

The study, published today in JAMA Network Open, tracked patients hospitalized for hip fractures in Victoria, Australia from March 2013 through June 2018, who had used gabapentinoids before the injury.

13 Nov 2024

GLP-1 agonists linked to fewer hospitalizations in alcohol use disorder patients

A new joint study by the University of Eastern Finland and Karolinska Institutet in Sweden found that the GLP-1 agonists semaglutide and liraglutide, which are used for treating diabetes and obesity, were associated with fewer hospitalizations among individuals with alcohol use disorder, AUD.

13 Nov 2024

Scientists discover new breakthrough in weight loss and diabetes treatment

Scientists at the University of Copenhagen have discovered a new weight loss drug target that reduces appetite, increases energy expenditure, and improves insulin sensitivity without causing nausea or loss of muscle mass.

13 Nov 2024

Cannabinol enhances sleep in rats, study shows

Research by scientists at the University of Sydney has identified a constituent in the cannabis plant that improves sleep.

11 Nov 2024

GLP-1 and SGLT2 inhibitors show promise in preventing recurrent stroke and heart attack

GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or weight loss, may reduce the risk of heart attack, second strokes and death in adults who had an initial stroke, according to a preliminary study to be presented at the American Heart Association's Scientific Sessions 2024.

11 Nov 2024

Beta blockers linked to increased depression in heart attack patients

All patients who have had a heart attack are typically treated using beta blockers. According to a Swedish study conducted earlier this year, this drug is unlikely to be needed for those heart patients who have a normal pumping ability.

11 Nov 2024

Novel bladder cancer treatment gains MHRA approval in the UK

Johnson & Johnson has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for BALVERSA®▼ (erdafitinib) as a monotherapy for the treatment of adults with unresectable or metastatic urothelial carcinoma (UC), the most common form of bladder cancer.

9 Nov 2024

Adipo Therapeutics shares results of studies on potential obesity treatment

Adipo Therapeutics LLC, a late-stage, preclinical biopharmaceutical company developing a potential treatment for obesity and related metabolic disorders, presented data from two studies at the annual meeting of The Obesity Society in San Antonio.

7 Nov 2024

Many veterans pursue psychedelics for healing or spiritual exploration

Most U.S. military veterans who have used psychedelics reported in a recent study that they pursued the substances for healing or spiritual exploration, and over 80% said they benefited from the experience – even those who had challenging outcomes.

6 Nov 2024

Rice bioengineers uncover why IL-12 immunotherapy loses effectiveness

A team of Rice University bioengineers has developed a mathematical model that clarifies why interleukin-12 (IL-12) ⎯ a potent immune-boosting protein that holds promise for cancer treatment ⎯ loses effectiveness over time when used as an immunotherapeutic.

6 Nov 2024

Curcumin compound reactivates Epstein–Barr virus, offering safer cancer therapy

A novel curcumin derivative, C210, activates the Epstein–Barr virus (EBV) lytic cycle without producing infectious virions by disrupting HSP90. This discovery opens avenues for safer EBV-positive cancer therapies.

5 Nov 2024

No evidence Trump’s drug program for terminal patients saved ‘thousands’ of lives

Former President Donald Trump has boasted in recent months about "Right To Try," a law he signed in 2018. It's aimed at boosting terminally ill patients' access to potentially lifesaving medications not yet approved by the Food and Drug Administration.

5 Nov 2024

Celastrol's druggability, molecular targets, and nanocarrier delivery against chronic diseases

Announcing a new publication for Acta Materia Medica journal. Celastrol is an active compound from the root of Tripterygium wilfordii Hook F that shows great potential in the treatment of inflammation, cancer, neurodegeneration, diabetes, and obesity.

5 Nov 2024